Riskpilot← Back to searchSign inGet full accessBJØRNDAL APOTEK AS
ASActiveOrg 922528969Granbergstubben 16, 1275 OsloRetail sale of pharmaceutical products · NACE 4773Est. 201920 employees
Revenue 2024
NOK 13,9M
+3% vs 2023
EBITDA margin
1.3%
-53% vs 2023
Equity ratio
-21.8%
Financial strength
Net profit 2024
NOK 34K
-80% vs 2023
| Revenue | NOK 13,9M | +3% |
| EBITDA | NOK 181K | -53% |
| Net profit | NOK 34K | -80% |
| Total assets | NOK 2,3M | -20% |
| Equity | NOK -508K | +56% |
| Employees | 20 | — |
Legal name
BJØRNDAL APOTEK AS
Org number
922528969
Legal form
Aksjeselskap
NACE code
4773 · Retail sale of pharmaceutical products
Founded
22. mars 2019
Share capital
NOK 1 800 000
Employees
20 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap.
Company purpose
Eie og drive apotek og alt hva hermed står i forbindelse.
Address
Granbergstubben 16, 1275 Oslo
Phone
+4722752200
Email
bjorndal@dittapotek.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 10 880 | 12 293 | 11 806 | 13 481 | 13 940 |
| Staff expenses | −1 862 | −2 619 | −2 500 | −1 910 | −2 022 |
| EBITDA | 41 | −489 | −564 | 385 | 181 |
| Depreciation & amort. | −156 | −156 | −156 | −156 | −133 |
| EBIT | −114 | −645 | −720 | 229 | 48 |
| Net financials | −58 | −51 | −71 | −57 | −14 |
| Profit before tax | −173 | −696 | −791 | 172 | 34 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −173 | −696 | −791 | 172 | 34 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2 037 | 2 401 | 1 816 | 2 917 | 2 328 |
| Equity | −628 | −923 | −1 315 | −1 142 | −508 |
| Long-term debt | 1 084 | 790 | 485 | 167 | 300 |
| Short-term debt | 1 580 | 2 534 | 2 646 | 3 892 | 2 537 |
| Total debt | 2 665 | 3 324 | 3 131 | 4 059 | 2 837 |
EBITDA margin
1.3%
This company
15.8%
Market median
-92% vs market
20202024
Equity ratio
-21.8%
This company
38.2%
Market median
-157% vs market
20202024
Return on equity
3396900.0%
This company
18.4%
Market median
+18461313% vs market
20202024
Net profit margin
0.2%
This company
8.1%
Market median
-98% vs market
20202024
Asset turnover
5.99×
This company
1.12×
Market median
+435% vs market
20202024
Debt / equity
5.58×
This company
0.62×
Market median
-800% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
LA Chief Executive Officer | Chief Executive Officer | 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Chairman | 2019 | |
| Board of Directors | 2019 | |
| Board of Directors | 2019 | |
| Board of Directors | 2019 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 33.33% | 33.33% | 2024 | |
| Company | 33.33% | 33.33% | 2024 | |
| Company | 33.33% | 33.33% | 2024 | |
| Company | 25% | 25% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Apoinvest Holding As
BJØRNDAL APOTEK AS Board members of BJØRNDAL APOTEK AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Luqman Ahsan | Chief Executive Officer | 0 companies |
| Morten Frogner | Chairman | 0 companies |
| Jan Arne Frogner | Board of Directors | 0 companies |
| Einar Mathias Teigen Rasch-Halvorsen | Board of Directors | 0 companies |
| Gulzeb Aziz | Board of Directors | 0 companies |